Your AI-Trained Oncology Knowledge Connection!
Three-year results from the ENESTnd trial show continued superiority of nilotinib over imatinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase, according to a new paper published online ahead of print in Leukemia in June.
Nilotinib offers good results for patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase who are resistant or intolerant of imatinib, according to 48-month follow-up results of a phase II study.
Observations made in the study of the leukemias have contributed to our understanding of malignancy in general and to our ability to treat cancer patients with drugs.
The article by Drs. Stein and Tallman is an excellent summary indicating that several different approaches may lead to the cure of acute promyelocytic leukemia (APL).
The management of patients with acute promyelocytic leukemia (APL) has been transformed over the course of the last two decades following the introduction of successful molecularly targeted therapies-all-trans retinoic acid (ATRA) and arsenic trioxide (ATO)- which act in concert to induce degradation of the PMLRARα oncoprotein formed by the chromosomal translocation t(15;17)(q22;q21).
The treatment of APL in the modern era is a success of modern hematology. In this review we have attempted to plant the seeds of understanding regarding how diagnosis and treatment of APL will be pursued over the next decade.
Updated clinical data from the pivotal phase II global PACE trial of ponatinib confirm its impressive antileukemic activity in patients with chronic myeloid leukemia or Philadelphia-chromosome-positive acute lymphoblastic leukemia at all stages who are resistant or intolerant to dasatinib or nilotinib.
Bendamustine plus rituximab should be considered as the preferred first-line treatment of follicular and indolent lymphomas, and the elderly with mantle cell lymphoma.
In a phase I study the targeted drug crizotinib, a small molecule inhibitor of anaplastic lymphoma kinase and met proto oncogene, delayed or eliminated signs of tumor growth in pediatric patients with aggressive cancers.
A new study has identified independent risk factors for the development of non-Hodgkin lymphoma (NHL) including high fetal growth, older age of the mother, low birth order, and male sex. A family history of NHL in either parent or sibling was found to be the strongest risk factor.
Researchers at the University of Pennsylvania have identified a protein that could be targeted to turn off B-cell lymphomas. The protein, CD19, was found to be a major regulator of B-cell neoplastic growth driven by the MYC oncogene.
Dr. Hoppe and colleagues present a strong case supporting the use of proton therapy (PT) for the treatment of patients with Hodgkin lymphoma (HL).
Proton radiotherapy is here to stay. Despite the high initial cost, the number of proton therapy machines in the United States and elsewhere is increasing rapidly.[1] The major questions now relate to defining and optimizing their appropriate use.
If there is one disease for which patients have experienced a significant improvement in the cure rate over the past 10 years, it is diffuse large B-cell lymphoma (DLBCL).
In their article in this issue of ONCOLOGY, Nastoupil, Rose, and Flowers give a very careful assessment of the options for treating diffuse large B-cell lymphoma (DLBCL), with a focus on the importance of dose density in improving outcomes in this disease.
This article examines clinical and biological features of DLBCL patients with poor outcomes, and reviews recent studies addressing alternatives to standard front-line management strategies together with unresolved questions.
This review addresses the rationale and evidence for-and the challenges, cost implications, and future development of-proton therapy as an important part of the treatment strategy in Hodgkin lymphoma.
Leukemias and lymphomas are estimated to contribute up to 7% of all new malignant cases in the United States.[1]
The leukemias and lymphomas represent a group of heterogeneous myeloid or lymphoid clonal stem cell disorders with variable clinical presentation, pathological characteristics, prognosis and recommendations for treatment.[1]
The management of leukemias and lymphomas now includes the use of many targeted therapies. Nurses need to have an understanding of the targeted therapies and their side effects so they can appropriately manage the side effects that their patients with leukemias and lymphomas may experience.
Two researchers from the Mayo Clinic have published an editorial calling for new approaches in the treatment of AML, arguing that "using the same old drugs in different doses or different schedules is not going to cut it."
Cancer treatment is undergoing significant developments and entering the new golden era of genomics which has true potentials for the promise of personalized medicine. Large-scale sequencing is changing our understanding of malignant disorders particularly acute myeloid leukemia.
Inotuzumab ozogamicin has achieved a markedly long antitumor response in patients with refractory or relapsed indolent B-cell non-Hodgkin lymphoma (NHL) in an ongoing phase II study. Interim findings were reported by lead investigator Kenneth Luu, PhD, associate director of Pfizer global R&D.
A combination of TL32711, an investigational second mitochondrial-derived activator of caspases (Smac), and tumor necrosis factor-related apoptosis inducing ligand at low concentrations produced marked apoptosis in germinal center lines, with minimal to no effect for each agent alone.
Preliminary findings of a phase I/II randomized clinical trial indicate that SGI-110, a novel DNA methylation inhibitor, is safe, well tolerated and efficacious in patients with acute myelogenous leukemia.
